ScripRoivant subsidiary Immunovant announced positive Phase III data for its neonatal fragment crystallizable receptor (FcRn) inhibitor batoclimab in myasthenia gravis (MG), but a key piece of the update i
Pink SheetDespite the “chaotic” early days, experts said plenty of opportunities are available to work with President Donald Trump’s new administration, although the biopharma industry must frame lobbying effor
Pink SheetUpcoming negotiations to reauthorize the US Food and Drug Administration’s prescription drug user fee program should be viewed as a chance to make the program more efficient in the face of an administ
ScripAdvice For Working With Trump The biotech industry is only about one month into working with a new administration in the US following the inauguration of Donald Trump as president – and the pace of